Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PepGen Inc. (PEPG – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and BridgeBio Pharma (BBIO – Research Report).
PepGen Inc. (PEPG)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. on January 26 and set a price target of $24.00. The company’s shares closed last Tuesday at $10.93.
According to TipRanks.com, Matteis is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PepGen Inc. with a $23.67 average price target, a 216.0% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $21.00 price target.
See the top stocks recommended by analysts >>
Crispr Therapeutics AG (CRSP)
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG today and set a price target of $80.00. The company’s shares closed last Tuesday at $64.48.
According to TipRanks.com, Tuerkcan is a 3-star analyst with an average return of
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $85.80, implying a 31.8% upside from current levels. In a report issued on January 18, Oppenheimer also maintained a Buy rating on the stock with a $102.00 price target.
BridgeBio Pharma (BBIO)
BridgeBio Pharma received a Hold rating and a $37.00 price target from BMO Capital analyst Kostas Biliouris today. The company’s shares closed last Tuesday at $36.09.
According to TipRanks.com, Biliouris is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BridgeBio Pharma with a $48.13 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PEPG:
